Alteration of Fc-fusion protein serum half-lives by mutagenesis
The present invention provides for a modified Fc-fusion protein in which at least one amino acid from the heavy chain constant region selected from the group consisting of amino acid residues 250, 314, and 428 is substituted with another amino acid which is different from that present in the unmodified Fc-fusion protein, thereby altering the binding affinity for FcRn and/or the serum half-life in comparison to the unmodified Fc-fusion protein.
1. A modified Fc-fusion protein comprising an extracellular domain of tumor necrosis factor receptor II, interleukin 13, or a CD2 binding portion of lymphocyte function associated antigen 3 (LFA-3) fused to an Fc region of IgG isotype, wherein the Fc region comprises amino acid residues 250 and 428, EU numbering, that differ from the residues present in an unmodified Fc-region by amino acid residue 250 being glutamic acid or glutamine and amino acid residue 428 being leucine or phenylalanine.
2. The modified fusion protein of claim 1 , wherein the IgG isotype is IgG1.
3. The modified fusion protein of claim 1 , wherein amino acid residue 250 is glutamine and amino acid residue 428 is leucine.
4. The modified Fc-fusion protein of claim 1 , further comprising a linker and a hinge region between the extracellular domain of tumor necrosis factor receptor II, interleukin 13, or the CD2 binding portion of lymphocyte function associated antigen 3 and the Fc region.